Pernix Therapeutics Revenue, Profits - PTX Annual Income Statement

Add to My Stocks
$0.85 $0.05 (5.56%) PTX stock closing price Sep 19, 2018 (Closing)

Financial statements provide us with a way to gain insights and undertake the fundamental analysis of a company. Checking Pernix Therapeutics stock price alone is not sufficient. The income statement gives the investor an understanding of the topline or revenue and bottomline or profit numbers of the company and helps investors evaluate if a company has been growing or not. When compared with the corresponding income statement from the past, the latest income statement shows how revenue has grown from 140.85M to 146.06M and how operating and non operating activities have impacted the PTX stock. Revenue for year 2017 is $146.06M and has increased from $140.85M year on year as is evident when you compare the latest figures in the latest Pernix Therapeutics profit and loss statement with those of the prior corresponding period. Also see Pernix Therapeutics assets and Pernix Therapeutics free cash flow for a complete valuation of PTX stock.

View revenue and profit details for latest and last 10 financial years.
show more
View Previous Years
View Next Years
Fiscal year is Jan - Dec2017201620152014201320122011201020092008
Pernix Therapeutics Revenues or Net Sales
Cost Of Goods Sold (COGS)44.63M43.32M51.4M45.15M43.87M23.37M20.53M6.5M--
Pernix Therapeutics Gross Profit
Research & Development Expense-6.07M8.22M3.93M4.79M-----
Selling General & Admin Expense83.89M145.64M122.77M69.86M82.18M35.69M23.73M14.86M1.64M1.64M
Income Before Depreciation Depletion Amortization16.75M-54.19M-6.55M2.78M-45.98M1.51M15.41M10.85M-1.64M-1.64M
Depreciation Depletion Amortization73.21M86.13M94.69M32.99M8.67M3.2M2.3M1.23M--
Non Operating Income16.64M9.03M-1.72M-12.31M--0.17M1.17M-1.82M
Interest Expense36.95M37.85M38.27M18.79M4.04M-----
Pernix Therapeutics Pretax Income
Provision for Income Taxes--7.06M-13.72M-20.75M-0.37M4.58M1.48M--
Investment Gains Losses----------
Other Income----------
Income Before Extraordinaries & Disc Operations-77.14M-169.59M-148.31M-35.28M-25.63M-1.41M8.34M9.3M-1.54M-
Extraordinary Items & Discontinued Operations--------1.02M-0.71M
Pernix Therapeutics Profit/ Loss (Net Income)
Average Shares used to compute Diluted EPS10.71M7.83M5.33M3.79M3.64M2.81M2.45M2.34M2.09M-
Average Shares used to compute Basic EPS10.71M7.83M5.33M3.79M3.64M2.81M2.4M2.34M2.09M-
Income Before Nonrecurring Items-93.47M-115.46M-39.6M7.25M-13.91M-0.76M9.32M8.73M9.24M-
Income from Nonrecurring Items16.33M-54.13M-108.72M-42.53M-11.73M-0.65M-0.97M---
Pernix Therapeutics Earnings Per Share Basic Net
Pernix Therapeutics Earnings Per Share Diluted Net
EPS Diluted Before Nonrecurring Items-8.20-14.76-7.401.10-3.80-0.303.803.704.40-
Preferred Dividends Acc Pd----------
Dividends Common----------
Dividend Per Share Common0.
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years

It is very helpful to read a report on Pernix Therapeutics stock analysis. An investor must check the following items in an income statement:

  • Top line: The word topline comes from the fact that the first line of an income statement refers to sales numbers. If you check you will find that PTX stock has a topline or revenue of $146.06M for 2017 as per this Pernix Therapeutics revenue chart. Investors look for stocks with a growing top line.
  • Bottom line: This refers to the last line in a profit and loss statement and denotes the net profit or loss for a particular period. The figure currently stands at $-77.14M for Pernix Therapeutics for 2017. This figure is arrived at after deducting all operating expenses, interest, and taxes from revenue.

The income statement is also called the profit and loss statement. Apart from the PTX income statement, one can check the Pernix Therapeutics historical stock prices to check how the price has moved with time.

Pernix Therapeutics Income Statement - Key Financial Ratios

PS Ratio (price sales ratio)
Dividend Yield